The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

Perrigo Rx Divestment Sees Firm Drop Out Of Top Five As Sun Rises

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Generics Bulletin Top 50 2022
A new order is emerging for the leading companies • Source: Shutterstock

In the ever-evolving global generics and biosimilars industry, one constant that can be relied upon is change. Even as the upheaval of the COVID-19 pandemic recedes, fresh political and economic pressures are being felt by firms across the world, while specific local trends are also playing their part in the fortunes of regional players.

Alongside these external factors, active strategic decisions made by the world’s off-patent industry leaders are also significantly reshaping the competitive...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Company Rankings

More from Market Intelligence